OGN

Handel nachbörslich: 15.15 0.05 +0.33%

Organon Co (OGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Organon Co Stock (OGN) Company Profile

Healthcare (1196)

551-430-6000

30 HUDSON STREET, JERSEY CITY

Nächster Verdiensttermin

Neueste SEC-Einreichungen

OGN's Discussions on Twitter

Vergleichen Sie OGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OGN	15.10	3.89B	6.41B	1.30B	646.00M	2.29
LLY	727.20	683.37B	40.86B	8.37B	-2.28B	5.4193
NVO	99.81	446.14B	39.36B	13.79B	9.83B	2.4077
JNJ	154.77	353.35B	87.70B	14.68B	19.03B	13.47
ABBV	166.28	293.80B	55.53B	5.12B	15.62B	3.65
MRK	96.56	242.49B	63.17B	12.15B	14.84B	1.80

Organon Co Stock (OGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-09-06	Herabstufung	JP Morgan	Neutral → Underweight
2023-11-03	Herabstufung	Goldman	Buy → Neutral
2023-09-21	Eingeleitet	Barclays	Overweight
2023-03-16	Eingeleitet	Raymond James	Outperform
2022-10-14	Herabstufung	BofA Securities	Neutral → Underperform
2022-09-06	Hochstufung	Piper Sandler	Neutral → Overweight
2022-08-05	Herabstufung	BofA Securities	Buy → Neutral
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-06	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-10-07	Eingeleitet	Piper Sandler	Neutral
2021-09-01	Eingeleitet	BofA Securities	Buy
2021-07-22	Eingeleitet	Citigroup	Buy
2021-06-15	Eingeleitet	JP Morgan	Neutral
2021-06-11	Eingeleitet	Morgan Stanley	Equal-Weight
2021-06-10	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

Organon Co Aktie (OGN) Neueste Nachrichten

Finanzdaten der Organon Co-Aktie (OGN)

Organon Co (OGN)

Organon Co Stock (OGN) Company Profile

Vergleichen Sie OGN mit anderen Aktien

Organon Co Stock (OGN) Upgrades & Downgrades

Organon Co Aktie (OGN) Neueste Nachrichten

Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune

Organon: 7% Yield, 4x P/E, Big Upside Potential (NYSE:OGN) - Seeking Alpha

(OGN) Proactive Strategies - Stock Traders Daily

Organon & Co. (NYSE:OGN) Shares Sold by Principal Financial Group Inc. - MarketBeat

Organon & Co. (NYSE:OGN) Stock Holdings Decreased by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) - Seeking Alpha

Organon & Co (OGN) Stock Price Down 3.48% on Nov 12 - GuruFocus.com

Amalgamated Bank Sells 34,385 Shares of Organon & Co. (NYSE:OGN) - MarketBeat

Los Angeles Capital Management LLC Boosts Stake in Organon & Co. (NYSE:OGN) - MarketBeat

Acorn Financial Advisory Services Inc. ADV Takes $743,000 Position in Organon & Co. (NYSE:OGN) - MarketBeat

Van ECK Associates Corp Increases Holdings in Organon & Co. (NYSE:OGN) - MarketBeat

Philip James Wealth Mangement LLC Invests $15.39 Million in Organon & Co. (NYSE:OGN) - MarketBeat

Ex-Dividend Reminder: American Water Works, Essential Utilities Inc and Organon - Nasdaq

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem - Yahoo Finance

Income Investors Should Know That Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon - Simply Wall St

Organon & Co (OGN) Stock Price Up 2.82% on Nov 7 - GuruFocus.com

FDA extends Organon's VTAMA cream review to March 2025 By Investing.com - Investing.com Canada

Organon & Co. (NYSE:OGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance

Relative Strength Alert For Organon - Nasdaq

Organon updates outlook as FDA delays VTAMA label expansion - MSN

Organon reports FDA extension of target action date of review of Vtama sNDA - TipRanks

Organon’s VTAMA Cream FDA Review Extended to 2025 - TipRanks

Organon stock on watch as FDA delays VTAMA label (OGN:NYSE) - Seeking Alpha

FDA extends Organon's VTAMA cream review to March 2025 - Investing.com

(tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older - Business Wire

Organon's SWOT analysis: stock outlook amid VTAMA potential and biosimilar growth - Investing.com

Organon & Co (OGN) Stock Price Down 6.38% on Nov 4 - GuruFocus.com

Organon & Co. (NYSE:OGN) Trading Down 4.4%Should You Sell? - MarketBeat

The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - Simply Wall St

Organon China’s License and Supply Agreement with Shanghai Bao Pharmaceuticals - Global Legal Chronicle

(OGN) Technical Pivots with Risk Controls - Stock Traders Daily

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28 - Yahoo Finance

Net Present Value Model: Organon & Co’s Pertuzumab biosimilar - GlobalData

Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN

Private Management Group Inc. Has $36.23 Million Holdings in Organon & Co. (NYSE:OGN) - MarketBeat

FDA accepts Organon BLA for Prolia/Xgeva biosimilar - MSN

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023) - Yahoo Finance

Organon & Co. (NYSE:OGN) to Issue $0.28 Quarterly Dividend - MarketBeat

Organon & Co (OGN) Shares Up 5.61% on Oct 31 - GuruFocus.com

Organon: Q3 Earnings Snapshot - The Advocate

Organon & Co. Reports Strong Third Quarter 2024 Results - TipRanks

Organon Co earnings missed by $0.03, revenue topped estimates - Investing.com Australia

Organon (OGN) Q3 Earnings and Revenues Beat Estimates - MSN

Earnings call: Organon announced a revenue of $1.6 billion - Investing.com

Earnings call: Organon announced a revenue of $1.6 billion By Investing.com - Investing.com UK

Organon Reports Results for the Third Quarter Ended September 30, 2024 - BioSpace

Organon & Co Q3 2024 Earnings: EPS Soars to $1.38, Revenue Hits $1.582 Billion, Surpassing Estimates - GuruFocus.com

Finanzdaten der Organon Co-Aktie (OGN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie OGN